Skip to main content
. 2020 Oct 30;12(11):1042. doi: 10.3390/pharmaceutics12111042

Figure 4.

Figure 4

Delivery efficacy of F2, F8, F11, F17 formulations with luciferase mRNA. (a) Efficacy of the four lead formulations before and after nebulization in lung as measured in total flux of luminescence 6 h after intratracheal delivery of 1.5 µg of total mRNA. (b) Representative images of the luciferase expression in the lungs, heart, liver, and kidneys measured by in vivo imaging system (IVIS) imaging.